Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunotherapy
Data on cancer vaccines immunotherapy reported by researchers at Herlev University, Department of Hematology
April 15th, 2009
Fresh data on cancer vaccines are presented in the report 'The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.' "Among the relatively large number of known tumor-associated antigens (TAA) which are recognized by human CD8 T-cells, Melan-A/MART-1 is one of the most-if not the most-frequently used target for anti-cancer vaccines in HLA-A2 + melanoma patients. In this study, we analyzed the killing of a large panel of melanoma cells by a high avidity, MART-1-specific T-cell clone or a MART-1-specific, polyclonal T-cell culture," researchers in Herlev, Denmark report. "Strikingly, we observed that the...
Source: Vaccine Weekly (2009-04-15)
|
